Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial 2024-04-22 20:30
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial 2024-04-15 20:30
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy 2024-01-24 21:30
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024 2023-11-28 22:00
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston 2023-10-13 20:00
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update 2023-09-26 20:51
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention 2023-05-31 20:58
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference 2023-03-30 21:00
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial 2022-12-22 20:30
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial 2022-12-14 21:52
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients 2022-10-10 20:00
1